Comments
Drug firm Zydus Cadila on Monday said it has received final nod from the US health regulator to market Chlorthalidone tablets, used to treat high blood pressure.
Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Chlorthalidone tablets in the strengths of 25 milligrams (mg) and 50 mg, the company said in a Bombay Stock Exchange (BSE) filing.
Chlorthalidone is used to treat high blood pressure (hypertension). It is also used to treat fluid retention (edema) in people with congestive heart failure, cirrhosis of the liver or kidney disorders or edema caused by taking steroids or estrogen.
Zydus Cadila said the product will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad.
The group now has 266 approvals and has filed over 350 abbreviated new drug applications (ANDAs) since the commencement of its filing process, Zydus Cadila said.
Shares of Cadila Healthcare, the listed entity of the group, were trading 3.02 per cent lower at Rs 280.95 apiece on BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.